JFJuliana Fittipaldi

Juliana Fittipaldi

*This is an algorithmically generated author record based on publicly available information.

Juliana Fittipaldi has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Metabolic dysfunction‐associated liver disease predicts incident liver fibrosis in people with HIV mono‐infection: A cohort study

    by Juliana Fittipaldi, Sandra W. Cardoso, Estevão Portela Nunes, Cristiane Fonseca De Almeida, Patricia Dias De Brito, Valdilea G. Veloso, Beatriz Grinsztejn, Hugo Perazzo

    Introduction: Metabolic dysfunction‐associated liver disease (MASLD) might progress to cirrhosis. We aimed to evaluate the association of MASLD with the risk of developing clinically significant fibrosis (CSF) in people living with HIV (PLWH). Methods: PLWH have been followed up since 2015 in the PROSPEC‐HIV cohort (NCT02542020) with questionnaires, blood samples, and transient elastography (TE) on the same day. Participants with viral hepatitis, who were c‐ART naïve, those with CSF at baseline or unreliable TE examinations and who lost follow‐up were excluded. Liver steatosis and fibrosis were assessed by TE‐Controlled Attenuation Parameter (CAP) and TE‐liver stiffness measurement (LSM), respectively. MASLD was defined as the presence of steatosis (CAP ≥263 dB/m) at baseline with at least one cardiometabolic risk factor without hazardous alcohol intake [Alcohol Use Disorders Identification Test (AUDIT) score 2 and 17.8% with MASLD) were included. During a median follow‐up of 7.4 (IQR, 6.0–8.3) years, 11.8% ( n = 36) participants developed CSF. The cumulative incidence of CSF at the 8th year was higher in PLWH with MASLD than in those without (30.1% [95% CI, 18.0–47.6] vs. 8.8% [95% CI, 5.4–14.2], p < 0.001). MASLD at baseline was significantly associated with the incidence of CSF in a multivariate Cox model (adjusted hazard ratio [aHR] = 2.92 [95% CI, 1.40–6.09]). Conclusion: MASLD increased the risk of liver fibrosis in people with HIV mono‐infection under c‐ART.